By Recursion PharmaceuticalsLearning Objectives
- Understand what AI drug discovery is and how Recursion's approach works
- Evaluate the Exscientia merger and its impact on end-to-end capabilities
- Assess the challenges and timeline realities of AI-driven pharmaceutical development
What Is Recursion Pharmaceuticals?
Recursion Pharmaceuticals (NASDAQ: RXRX) uses AI and biology-scale datasets to discover new drugs faster. The traditional drug development process takes 12+ years and costs $2+ billion per approved drug. Recursion's AI platform aims to compress this to 4-5 years by using machine learning to identify promising drug candidates from massive biological datasets.
After merging with Exscientia in November 2024 ($688 million all-stock deal), Recursion now offers end-to-end AI drug discovery — from target identification through candidate optimization — the most comprehensive AI-native pharmaceutical platform.
Recursion OS
The Recursion OS is an AI-native drug discovery platform that integrates:
- Biology exploration — massive proprietary datasets of cellular responses to chemical and genetic perturbations
- Precision chemistry (from Exscientia) — automated small-molecule synthesis and optimization
- Clinical development — AI-assisted trial design and patient selection
Pipeline
| Stage | Programs |
|---|---|
| Clinical (5 programs) | Oncology, rare disease, neuroscience, immunology |
| Discovery (~15 programs) | Internal and partnership efforts across multiple therapeutic areas |
| Pharma Partnerships | Sanofi, Roche, Bayer, Merck — $500+ million in upfront and milestone payments |
Company Details
| Detail | Info |
|---|---|
| Company | Recursion Pharmaceuticals (NASDAQ: RXRX) |
| CEO | Najat Khan, Ph.D. (since January 2026; former J&J Chief Data Science Officer) |
| Founder/Chairman | Chris Gibson, Ph.D. |
| Headquarters | Salt Lake City, Utah |
| Market Cap | ~$1.79 billion |
| Revenue (2025) | ~$74 million |
| Cash Position | $755 million (runway through 2027) |
| Exscientia Merger | $688 million all-stock (November 2024) |
| Website | recursion.com |
⚠️Warning
AI drug discovery is promising but unproven at scale. No AI-discovered drug has yet completed Phase 3 trials and reached market approval. Recursion's stock is down approximately 88% from its highs, reflecting market skepticism about AI drug discovery timelines. The $755 million cash position provides runway through 2027, but clinical success is not guaranteed.
Key Takeaways
- Recursion uses AI and biology-scale datasets to compress drug discovery from 12+ years to 4-5 years; merged with Exscientia for end-to-end capabilities
- 5 clinical programs in oncology, rare disease, neuroscience, and immunology; $500+ million in pharma partnership milestones
- Stock down ~88% from highs reflects market skepticism; AI drug discovery remains unproven at scale but Recursion has the largest dataset and deepest partnerships
